Osiris Announces a Peer-Reviewed Publication Reporting the Use of Placental Membranes for Refractory Cutaneous Sinus Tracts of Surgical Origin

COLUMBIA, Md., Oct. 05, 2017 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer reviewed manuscript entitled “Placental Membranes for Management of Refractory Cutaneous Sinus Tracts of Surgical Origin: A Pilot Study” has been published in The Journal of the American College of Clinical Wound Specialists and is available online.

Despite advances in surgical techniques, postoperative complications such as infection, retained foreign body, seroma or hematoma may lead to the development of a sinus tract. A sinus tract, also referred to as wound tunneling, is a cutaneous opening with a narrow passageway that tracks in one direction underneath the tissues and is oftentimes blind ended or accompanied by drainage. Conservative wound care failure may necessitate further surgical interventions that are associated with high risk for complications and prolonged hospitalization. The purpose of the published study was to assess the clinical utility of placental products as an alternative to surgical treatment for refractory cutaneous sinus tracts of surgical origin in twelve patients. The primary clinical analysis was the proportion of complete sinus tract depth resolution without exudate. Six patients received a viable cryopreserved placental membrane (vCPM) (Grafix®; Osiris Therapeutics, Inc., Columbia, MD), and another group of six patients received dehydrated amnion/chorion membrane. All of sinus tracts (6/6) were closed with vCPM incorporation and all 6 sinus tracts in vCPM group remained closed at the 1-year or longer follow up. No patients (0/6) treated by dehydrated amnion/chorion membrane achieved complete sinus tract closure. There were no infections attributed to the use of either graft. Results of this study show that there may be clinical benefits of viable intact cryopreserved placental membrane for the treatment for refractory exudative sinus tracts as an alternative to repeat surgical intervention.

About Grafix

Grafix is a cryopreserved placental membrane comprised of an extracellular matrix (ECM) rich in collagen, growth factors, and viable cells native to the tissue. Grafix is processed using Osiris’ proprietary technology; it is flexible and conforming and designed as a wound cover/barrier for application directly to hard-to-treat acute and chronic wounds, including but not limited to diabetic foot ulcers, venous leg ulcers and thermal burns.

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing, and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, the Company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine — including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in wound care, orthopedics, and sports medicine, including Grafix®, Stravix®, BIO4® (available exclusively through Stryker), and Cartiform® (available exclusively through Arthrex). Osiris, Grafix, Stravix and Cartiform are registered trademarks of Osiris Therapeutics, Inc., and BIO4 is a registered trademark of Howmedica Osteonics Corp. Osiris makes no claims concerning functional activities of Grafix or Stravix. Although well characterized in scientific literature and studies, preservation of tissue integrity including cells may not be indicative of clinical outcome. More information can be found on the Company’s website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Examples of forward-looking statements may include, without limitation, statements regarding the anticipated efficiencies and advantages of products or services and the likelihood of customer clinical adoption of new services. Although well characterized in scientific literature and studies, preservation of tissue integrity including cells may not be indicative of clinical outcome. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

 For additional information, please contact:

 Diane Savoie
Osiris Therapeutics, Inc.
(443) 545-1834